Skip to main content
University of Gothenburg
Image
People working together to push puzzle pieces together
Photo: Sergey Nivens/Shutterstock.com
Breadcrumb

Intervention in ESSENCE

Coming soon!

Overview of research programme

Our research programme is focused on clinical trials to investigate the phenotype and treatment of various ESSENCE conditions, i.e. neurodevelopmental disorders. Our team has for many years been engaged in international medication trials for ADHD and have also initiated several treatment trials to examine novel treatments for ADHD and other ESSENCE, including behavioral treatments for problem behaviors associated with ESSENCE impairments.  

 

Programme supervisors

  • Mats Johnson
  • Elisabeth Fernell

Collaborators

  • Christopher Gillberg
  • Carina Gillberg
  • Nouchine Hadjikani
  • Jacob Åsberg Johnels
  • Max Thorsson
  • Eva Billstedt

 

Past projects

We have been engaged as investigators and national coordinators in several international multi-centre randomised placebo-controlled trials (RCTs) of newly developed medications for ADHD in children and adolescents, trials which have served as a basis for the approval of these medications in Europe. We performed an RCT of Omega 3/6 treatment for children and adolescents with ADHD (2009), and an RCT of Omega 3/6 for reading ability in mainstream schoolchildren (2016). We did a small open pilot trial (2012) of a cognitive training method “Collaborative Problem Solving, CPS” for children and adolescents with ADHD and severe irritability/problem behaviours, and have recently completed a large RCT (under review for publication 2020) with a modified form of this method (Problem Resolution for ESSENCE; PR-ESSENCE) for children with autism and/or ADHD with similar severe problems. A large open trial of long-term (2 years) medication for ADHD is underway, looking at effectiveness in improving ADHD symptoms, functioning in school, family, with friends, in everyday activities, and quality of life. We have recently completed an observational cohort study investigating the phenotype of children and adolescents with a suspected neuroinflammatory condition called “Paediatric Acute-onset Neuropsychiatric Syndrome, PANS”.

 

 

Ongoing projects

A large (n=130) open trial of long-term (2 years) medication for ADHD will soon be completed, looking at effectiveness in improving ADHD symptoms, functioning in school, family, with friends and in everyday activities, and quality of life.

Future projects

An RCT (n=70) to test the PR-ESSENCE treatment model for children and adolescents placed in The Swedish National Board of Institutional Care’s (Statens institutionsstyrelse, SiS) youth treatment homes due to severe problem behaviours, risk-taking and conduct disorders is planned to start during the autumn 2020. A long-term follow-up study of the symptom and functional trajectory for our PANS cohort is ongoing, and an open-label trial of IVIG treatment for PANS is planned to start this autumn.